RSI (6): 44.684 (neutral-to-weak), not oversold enough to suggest a high-conviction bounce.
Moving averages: converging = consolidation/indecision rather than a clear uptrend.
Key levels: Pivot 21.581 (overhead); Support S1 20.58 then S2 19.962; Resistance R1 22.582 then R2 23.2.
Pattern-based forward bias: only modest expected drift (next day -0.36%, next week -0.16%, next month +0.87%)—not a strong immediate upside setup.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Open-interest put/call ratio 0.58 suggests positioning skews bullish (more call OI than put OI).
Activity: today’s total option volume is very low (5 calls, 0 puts) → limited real-time sentiment signal.
Volatility: 30D IV 46.42 with IV percentile 20.8 / IV rank 8.29 → IV is relatively low vs its history (options not pricing extreme moves).
Liquidity note: low volume means spreads/slippage risk and less reliable read-through from options flow.
Technical Summary
Sell
5
Buy
10
Positive Catalysts
keep upside targets above spot.
Neutral/Negative Catalysts
Near-term event risk: earnings scheduled 2026-02-04 (pre-market) can drive a sharp gap move.
News/estimates: last 3 months show 4 downward EPS revisions and 3 downward revenue revisions → deteriorating expectations.
Profitability pressure: last quarter showed sharp EPS and net income declines (suggesting margin/volume/mix headwinds).
Industry/competitive risk flagged in news: “cheaper alternatives may emerge by 2026,” potentially pressuring growth and pricing power.
Technical backdrop is not supportive (bearish MACD expansion) going into earnings.
Financial Performance
Latest quarter: 2025/Q4.
Revenue: $3.688B, +3.54% YoY (top-line growing).
Net income: $18M, -77.22% YoY (material profitability deterioration).
EPS: $0.22, -75.28% YoY (earnings power weakened sharply).
Gross margin: 7.08%, +2.91% YoY (slight margin improvement, but not enough to prevent large earnings drop—implies opex/other items or mix/volume effects weighed on bottom line).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent direction (last ~3 months): mixed-to-cautious—multiple price target cuts in early Nov after softer FY26 outlook, followed by modest target raises in late Jan.
Current street stance: mostly Neutral/Equal Weight with one notable Buy (Stifel).
Price targets cluster in the mid-$20s (Stifel $26, Barclays $25; several at $22–$24 range).
Wall St pros: potential upside if FY26 turns out overly conservative and production/mix improves; hedge fund accumulation supports the bull case.
Wall St cons: guidance/estimate cuts and profitability compression raise risk that the stock remains range-bound until earnings visibility improves.
Wall Street analysts forecast ADNT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADNT is 23.06 USD with a low forecast of 20 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ADNT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADNT is 23.06 USD with a low forecast of 20 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
5 Hold
1 Sell
Hold
Current: 25.210
Low
20
Averages
23.06
High
28
Current: 25.210
Low
20
Averages
23.06
High
28
JPMorgan
Neutral
maintain
$24 -> $28
AI Analysis
2026-02-06
New
Reason
JPMorgan
Price Target
$24 -> $28
AI Analysis
2026-02-06
New
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Adient to $28 from $24 and keeps a Neutral rating on the shares. The firm upped estimates post the fiscal Q1 beat.
Barclays
Equal Weight
maintain
$25 -> $27
2026-02-06
New
Reason
Barclays
Price Target
$25 -> $27
2026-02-06
New
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Adient to $27 from $25 and keeps an Equal Weight rating on the shares following the fiscal Q1 report. The firm says an attractive opportunity is emerging for the company in 2027 and 2028.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ADNT
